Phathom Pharmaceuticals, Inc. (PHAT)
8.30
-0.37
(-4.27%)
USD |
NASDAQ |
Sep 10, 12:28
Phathom Pharmaceuticals Debt to Equity Ratio : -1.603 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.603 |
| March 31, 2026 | -1.624 |
| December 31, 2025 | -1.345 |
| September 30, 2025 | -1.380 |
| June 30, 2025 | -1.416 |
| March 31, 2025 | -1.669 |
| December 31, 2024 | -2.188 |
| September 30, 2024 | -2.774 |
| June 30, 2024 | -2.166 |
| March 31, 2024 | -3.158 |
| December 31, 2023 | -6.129 |
| September 30, 2023 | -12.74 |
| June 30, 2023 | 12.47 |
| March 31, 2023 | -2.361 |
| December 31, 2022 | -2.862 |
| Date | Value |
|---|---|
| September 30, 2022 | -7.838 |
| June 30, 2022 | -13.49 |
| March 31, 2022 | 2.435 |
| December 31, 2021 | 1.266 |
| September 30, 2021 | 0.8704 |
| June 30, 2021 | 0.3749 |
| March 31, 2021 | 0.30 |
| December 31, 2020 | 0.2523 |
| September 30, 2020 | 0.3114 |
| June 30, 2020 | 0.257 |
| March 31, 2020 | 0.2236 |
| December 31, 2019 | 0.1034 |
| September 30, 2019 | -0.7729 |
| December 31, 2018 | -1.516 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
| Veru, Inc. | 0.0945 |
| Johnson & Johnson | 0.5771 |
| Eli Lilly & Co. | 1.621 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 327.08M |
| Total Liabilities (Quarterly) | 671.35M |
| Shareholders Equity (Quarterly) | -344.27M |
| Current Ratio | 1.924 |
| Net Debt Paydown Yield | 0.29% |